Compare · BDX vs PDEX
BDX vs PDEX
Side-by-side comparison of Becton Dickinson and Company (BDX) and Pro-Dex Inc. (PDEX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDX and PDEX operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BDX is the larger of the two at $52.78B, about 272.0x PDEX ($194.1M).
- BDX has been more active in the news (8 items in the past 4 weeks vs 2 for PDEX).
- BDX has more recent analyst coverage (25 ratings vs 0 for PDEX).
- Company
- Becton Dickinson and Company
- Pro-Dex Inc.
- Price
- -
- -
- Market cap
- $52.78B
- $194.1M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 8
- 2
- Recent ratings
- 25
- 0
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Pro-Dex Inc.
Pro-Dex, Inc. designs, develops, and manufactures powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and maxocranial facial markets. It also provides engineering, quality, and regulatory consulting services; and manufactures and sells rotary air motors to various industries. The company was founded in 1978 and is headquartered in Irvine, California.
Latest BDX
- BD to Announce Financial Results for its Fourth Quarter and Full Year of Fiscal 2026
- BD and Global Health Leaders Call for Accelerated Maternal Life Saving Measures Worldwide
- BD Strengthens Leadership in Peripheral Vascular Innovation with Positive AGILITY Trial Results
- BD Celebrates 65 Years of Manufacturing, Innovation and Community Partnership in Canaan
- BD Appoints Ferass Abuzaina as Worldwide President of Surgery
- BD and U.S. Government Launch Landmark Partnership to Expand U.S. Manufacturing and Strengthen America's Healthcare Resilience
- EVP, Chief Revenue Officer Feld Michael sold $13,961 worth of shares (76 units at $183.70) as part of a pre-agreed trading plan, decreasing direct ownership by 0.39% to 19,644 units (SEC Form 4)
- BD Celebrates 70 Years of Manufacturing, Innovation and Community Partnership in Sandy
- Arthur Hu to Join BD as Chief Information and Digital Officer
- BD Advances Intelligent Robotics to Transform the Future of Pharmacy Care at Fairview
Latest PDEX
- SEC Form DEFA14A filed by Pro-Dex Inc.
- SEC Form DEF 14A filed by Pro-Dex Inc.
- Pro-Dex Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- Chief Executive Officer Van Kirk Richard Lee Jr sold $45,412 worth of shares (765 units at $59.36) as part of a pre-agreed trading plan, decreasing direct ownership by 0.96% to 79,228 units (SEC Form 4)
- Chief Executive Officer Van Kirk Richard Lee Jr sold $1,165,290 worth of shares (19,235 units at $60.58) as part of a pre-agreed trading plan, decreasing direct ownership by 19% to 79,993 units (SEC Form 4)
- Chief Financial Officer Charlton Alisha sold $140,983 worth of shares (2,300 units at $61.30), decreasing direct ownership by 10% to 21,870 units (SEC Form 4)
- Pro-Dex Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 10-K filed by Pro-Dex Inc.
- Pro-Dex, Inc. Announces Fiscal 2026 Fourth Quarter and Full-Year Results
- Pro-Dex Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits